Trekking new ground: Overcoming medical and social impediments for extended criteria liver transplant recipients

Liver Transplantation

Volumn 18, Issue SUPPL.2, 2012, Pages

  McCaughan, Geoffrey W ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE;

ALCOHOL LIVER DISEASE; ANTIVIRAL THERAPY; ARTICLE; BILE DUCT CARCINOMA; BRAIN DISEASE; CHRONIC LIVER FAILURE; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; END STAGE LIVER DISEASE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HEPATOPULMONARY SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER GRAFT; LIVER METASTASIS; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; MAINTENANCE THERAPY; NARCOTIC DEPENDENCE; OBESITY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SOCIAL STATUS; SURGICAL MORTALITY;

COMORBIDITY; CORONARY ARTERY DISEASE; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; METHADONE; OPIATE SUBSTITUTION TREATMENT; PATIENT ADVOCACY; PATIENT SELECTION; TRANSPLANTATION;

EID: 84868138876     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23526     Document Type: Article

References (65)

1. Murray KF, Carithers RL Jr,; for AASLD. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-1432.
2. Transplantation Society of Australia and New Zealand. Organ transplantation from deceased donors: consensus statement on eligibility criteria and allocation protocols. http://www.tsanz.com.au/downloads/201123June- TSANZConsensusStatementVs1.1.pdf. Accessed July 2012.
3. Scientific Registry of Transplant Recipients. http://www.srtr.org. Accessed July 2012.
4. European Liver Transplant Registry. http://www.eltr.org. Accessed July 2012.
5. Australia & New Zealand Liver Transplant Registry. http://www.anzltr.org. Accessed July 2012.
6. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA,. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307-313.
7. Schaubel DE, Wolfe RA, Sima CS, Merion RM,. Estimating the effect of a time-dependent treatment by levels of an internal time-dependent covariate: application to the contrast between liver wait-list and post-transplant mortality. J Am Stat Assoc 2009; 104: 49-59.
8. Sharma P, Schaubel DE, Guidinger MK, Merion RM,. Effect of pretransplant serum creatinine on the survival benefit of liver transplantation. Liver Transpl 2009; 15: 1808-1813.
9. Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM,. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008; 8: 419-425.
10. Berg CL, Merion RM, Shearon TH, Olthoff KM, Brown RS Jr, Baker TB, et al. Liver transplant recipient survival benefit with living donation in the Model for Endstage Liver Disease allocation era. Hepatology 2011; 54: 1313-1321.
11. Weismüller TJ, Fikatas P, Schmidt J, Barreiros AP, Otto G, Beckebaum S, et al. Multicentric evaluation of Model for End-Stage Liver Disease-based allocation and survival after liver transplantation in Germany-limitations of the 'sickest first'-concept. Transpl Int 2011; 24: 91-99.
12. Quante M, Benckert C., Thelen A., Gabelein G., Bercker S., Kaisers U., Berg T., Jonas S., Five-year-experience with high-MELD recipients (>30 points)-single-centre results and re-evaluation of prognostic models for postoperative survival. Paper presented at: 24th International Congress of the Transplantation Society; July 15-19, 2012; Berlin, Germany.
13. Sam J, Nguyen GC,. Protein-calorie malnutrition as a prognostic indicator of mortality among patients hospitalized with cirrhosis and portal hypertension. Liver Int 2009; 29: 1396-1402.
14. Gunsar F, Raimondo ML, Jones S, Terreni N, Wong C, Patch D, et al. Nutritional status and prognosis in cirrhotic patients. Aliment Pharmacol Ther 2006; 24: 563-572.
15. Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, et al. Severe muscle depletion in patients on the liver transplant wait list-its prevalence and independent prognostic value. Liver Transpl; doi:10.1002/lt.23495.
16. Jones JC, Coombes JS, Macdonald GA,. Exercise capacity and muscle strength in patients with cirrhosis. Liver Transpl 2012; 18: 146-151.
17. Keswani RN, Ahmed A, Keeffe EB,. Older age and liver transplantation: a review. Liver Transpl 2004; 10: 957-967.
18. Lipshutz GS, Hiatt J, Ghobrial RM, Farmer DG, Martinez MM, Yersiz H, et al. Outcome of liver transplantation in septuagenarians: a single-center experience. Arch Surg 2007; 142: 775-781.
19. Aloia TA, Knight R, Gaber AO, Ghobrial RM, Goss JA,. Analysis of liver transplant outcomes for United Network for Organ Sharing recipients 60 years old or older identifies multiple Model for End-Stage Liver Disease-independent prognostic factors. Liver Transpl 2010; 16: 950-959.
20. Schwartz JJ, Pappas L, Thiesset HF, Vargas G, Sorensen JB, Kim RD, et al. Liver transplantation in septuagenarians receiving Model for End-Stage Liver Disease exception points for hepatocellular carcinoma: the national experience. Liver Transpl 2012; 18: 423-433.
21. Perkins JD,. Treatment of an elderly patient with hepatocellular carcinoma: counseling from the patient's point of view. Liver Transpl 2012; 18: 391-394.
22. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A,; for OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11-e22.
23. Germani G, Gurusamy K, Garcovich M, Toso C, Fede G, Hemming A, et al. Which matters most: number of tumors, size of the largest tumor, or total tumor volume? Liver Transpl 2011; 17 (suppl 2): S58-S66.
24. Schlitt HJ, Mornex F, Shaked A, Trotter JF,. Immunosuppression and hepatocellular carcinoma. Liver Transpl 2011; 17 (suppl 2): S159-S161.
25. Nguyen NT, Harring TR, Goss JA, O'Mahony CA,. Neuroendocrine liver metastases and orthotopic liver transplantation: the US experience. Int J Hepatol 2011; 2011: 742890.
26. Rosen CB, Heimbach JK, Gores GJ,. Liver transplantation for cholangiocarcinoma. Transpl Int 2010; 23: 692-697.
27. Murad SD, Kim WR, Therneau T, Gores GJ, Rosen CB, Martenson JA, et al. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology; doi:10.1002/hep.25629.
28. Panjala C, Nguyen JH, Al-Hajjaj AN, Rosser BA, Nakhleh RE, Bridges MD, et al. Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma. Liver Transpl 2012; 18: 594-601.
29. Hong JC, Jones CM, Duffy JP, Petrowsky H, Farmer DG, French S, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg 2011; 146: 683-689.
30. Ramsay M,. Pulmonary hypertension and liver transplantation. In:, Milan Z, ed. Cardiovascular Diseases and Liver Transplantation. New York, NY: Nova Science Publishers; 2011: 83-97.
31. Hollatz TJ, Musat A, Westphal S, Decker C, D'Alessandro AM, Keevil J, et al. Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension. Liver Transpl 2012; 18: 686-695.
32. Fauconnet P, Ho V, Pastor C, Schiffer E,. Hepatopulmonary syndrome. In:, Milan Z, ed. Cardiovascular Diseases and Liver Transplantation. New York, NY: Nova Science Publishers; 2011: 179-192.
33. Arguedas MR, Abrams GA, Krowka MJ, Fallon MB,. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003; 37: 192-197.
34. Lucey MR,. Liver transplantation in patients with alcoholic liver disease. Liver Transpl 2011; 17: 751-759.
35. Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365: 1790-1800.
36. Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, et al.; for Solid Organ Transplantation in HIV: Multi-Site Study Investigators. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18: 716-726.
37. Duclos-Vallée JC, Féray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, et al.; for THEVIC Study Group. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47: 407-417.
38. Barshes NR, DiBardino DJ, McKenzie ED, Lee TC, Stayer SA, Mallory GB, et al. Combined lung and liver transplantation: the United States experience. Transplantation 2005; 80: 1161-1167.
39. Wyatt K, et al. Reducing the load: the evolution and management of obesity and nonalcoholic steatohepatitis before liver transplantation. Liver Transpl 2012; 18.
40. Charlton MR, Wall WJ, Ojo AO, Ginès P, Textor S, Shihab FS, et al.; for International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl 2009; 15: S1-S34.
41. MÃller S, Henriksen JH,. Haemodynamic profile of patients with end-stage liver disease. In:, Milan Z, ed. Cardiovascular Diseases and Liver Transplantation. New York, NY: Nova Science Publishers; 2011: 1-30.
42. Carey WD, Dumot JA, Pimentel RR, Barnes DS, Hobbs RE, Henderson JM, et al. The prevalence of coronary artery disease in liver transplant candidates over age 50. Transplantation 1995; 59: 859-864.
43. Plotkin JS, Scott VL, Pinna A, Dobsch BP, De Wolf AM, Kang Y,. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl Surg 1996; 2: 426-430.
44. Findlay JY,. Coronary artery disease and liver transplantation. In:, Milan Z, ed. Cardiovascular Diseases and Liver Transplantation. New York, NY: Nova Science Publishers; 2011: 31-48.
45. Raval Z, Harinstein ME, Skaro AI, Erdogan A, DeWolf AM, Shah SJ, et al. Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol 2011; 58: 223-231.
46. Ehtisham J, Altieri M, Salamé E, Saloux E, Ollivier I, Hamon M,. Coronary artery disease in orthotopic liver transplantation: pretransplant assessment and management. Liver Transpl 2010; 16: 550-557.
47. Azarbal B, Poommipanit P, Arbit B, Hage A, Patel J, Kittleson M, et al. Feasibility and safety of percutaneous coronary intervention in patients with end-stage liver disease referred for liver transplantation. Liver Transpl 2011; 17: 809-813.
48. Raichlin E, Rosen CB, Dumitru I, Daly RC, Kushwaha SS,. Combined cardiac surgery and liver transplantation. In:, Milan Z, ed. Cardiovascular Diseases and Liver Transplantation. New York, NY: Nova Science Publishers; 2011: 139-158.
49. Gardner AI, Gibbs NM,. Valvular heart disease and liver transplantation. In:, Milan Z, ed. Cardiovascular Diseases and Liver Transplantation. New York, NY: Nova Science Publishers; 2011: 67-81.
50. Torregrosa M, Aguadé S, Dos L, Segura R, Gõnzalez A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005; 42: 68-74.
51. Bravo PE, Hage FG,. Hypertrophic obstructive cardiomyopathy in liver transplant patients. In:, Milan Z, ed. Cardiovascular Diseases and Liver Transplantation. New York, NY: Nova Science Publishers; 2011: 99-112.
52. Hennessey T, Backman SB, Cecere R, Lachapelle K, de Varennes B, Ergina P, et al. Combined heart and liver transplantation on cardiopulmonary bypass: report of four cases. Can J Anaesth 2010; 57: 355-360.
53. Kemmer N, Zacharias V, Kaiser TE, Neff GW,. Access to liver transplantation in the MELD era: role of ethnicity and insurance. Dig Dis Sci 2009; 54: 1794-1797.
54. Kemmer N, Neff GW,. Liver transplantation in the ethnic minority population: challenges and prospects. Dig Dis Sci 2010; 55: 883-889.
55. Yoo HY, Galabova V, Edwin D, Thuluvath PJ,. Socioeconomic status does not affect the outcome of liver transplantation. Liver Transpl 2002; 8: 1133-1137.
56. Hunt CM, Tart JS, Dowdy E, Bute BP, Williams DM, Clavien PA,. Effect of orthotopic liver transplantation on employment and health status. Liver Transpl Surg 1996; 2: 148-153.
57. Verna EC, Valadao R, Farrand E, Pichardo EM, Lai JC, Terrault NA, Brown RS Jr,. Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus. Liver Transpl 2012; 18: 461-467.
58. Volk ML, Biggins SW, Huang MA, Argo CK, Fontana RJ, Anspach RR,. Decision making in liver transplant selection committees: a multicenter study. Ann Intern Med 2011; 155: 503-508.
59. Hogan BE, Linden W, Najarian B,. Social support interventions: do they work? Clin Psychol Rev 2002; 22: 383-442.
60. Koch M, Banys P,. Methadone is a medication, not an addiction. Liver Transpl 2002; 8: 783-786.
61. Jiao M, Greanya ED, Haque M, Yoshida EM, Soos JG,. Methadone maintenance therapy in liver transplantation. Prog Transplant 2010; 20: 209-214.
62. Kanchana TP, Kaul V, Manzarbeitia C, Reich DJ, Hails KC, Munoz SJ, Rothstein KD,. Liver transplantation for patients on methadone maintenance. Liver Transpl 2002; 8: 778-782.
63. Liu LU, Schiano TD, Lau N, O'Rourke M, Min AD, Sigal SH, et al. Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation. Am J Transplant 2003; 3: 1273-1277.
64. Weinrieb RM, Barnett R, Lynch KG, DePiano M, Atanda A, Olthoff KM,. A matched comparison study of medical and psychiatric complications and anesthesia and analgesia requirements in methadone-maintained liver transplant recipients. Liver Transpl 2004; 10: 97-106.
65. Hancock MM, Craemer EM, Rossaro L,. Liver transplantation and methadone. http://www.hcvadvocate.org/hcsp/articles/Methadone-transplant.html. Accessed July 2012.